96 related articles for article (PubMed ID: 26782892)
1. Memantine Exacerbates Corrected QT Interval Prolongation in Alzheimer's Disease: A Case Report from an Unintentional Rechallenge.
Kajitani K; Yanagimoto K; Monji A; Maruyama T
J Am Geriatr Soc; 2016 Jan; 64(1):232-3. PubMed ID: 26782892
[No Abstract] [Full Text] [Related]
2. Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer's disease.
Igeta H; Suzuki Y; Motegi T; Sasaki A; Yokoyama Y; Someya T
Gen Hosp Psychiatry; 2013; 35(6):680.e9-10. PubMed ID: 23731891
[TBL] [Abstract][Full Text] [Related]
3. Memantine-associated renal impairment in a patient with Alzheimer's disease.
Horikawa N; Yamada H; Uchimura N
Psychiatry Clin Neurosci; 2013 Feb; 67(2):126. PubMed ID: 23438167
[No Abstract] [Full Text] [Related]
4. Effect of Memantine on QT/QTc Interval in a Healthy Korean Population.
Park JW; Kim KA; Park JY
Clin Pharmacol Drug Dev; 2021 Oct; 10(10):1209-1215. PubMed ID: 33761171
[TBL] [Abstract][Full Text] [Related]
5. Nightmares and memantine: a case report and review of literature.
Iraqi A; Hughes TL
J Am Med Dir Assoc; 2009 Jan; 10(1):77-8. PubMed ID: 19111861
[No Abstract] [Full Text] [Related]
6. Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease.
Jones RW; Bayer A; Inglis F; Barker A; Phul R
Int J Geriatr Psychiatry; 2007 Mar; 22(3):258-62. PubMed ID: 17243195
[TBL] [Abstract][Full Text] [Related]
7. Memantine for Alzheimer's disease.
Med Lett Drugs Ther; 2003 Sep; 45(1165):73-4. PubMed ID: 12968123
[No Abstract] [Full Text] [Related]
8. Use of memantine to treat Alzheimer's disease.
Gauthier S; Herrmann N; Ferreri F; Agbokou C
CMAJ; 2006 Aug; 175(5):501-2. PubMed ID: 16940271
[No Abstract] [Full Text] [Related]
9. Seizures associated with memantine use.
Peltz G; Pacific DM; Noviasky JA; Shatla A; Mehalic T
Am J Health Syst Pharm; 2005 Feb; 62(4):420-1. PubMed ID: 15745897
[No Abstract] [Full Text] [Related]
10. Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.
Waldemar G; Hyvärinen M; Josiassen MK; Kørner A; Lehto H; Wetterberg P
Int J Geriatr Psychiatry; 2008 Sep; 23(9):979-81. PubMed ID: 18229874
[No Abstract] [Full Text] [Related]
11. Pilot trial of memantine in primary progressive aphasia.
Johnson NA; Rademaker A; Weintraub S; Gitelman D; Wienecke C; Mesulam M
Alzheimer Dis Assoc Disord; 2010; 24(3):308. PubMed ID: 20798612
[No Abstract] [Full Text] [Related]
12. QT prolongation associated with memantine in Alzheimer's disease.
Takehara H; Suzuki Y; Someya T
Psychiatry Clin Neurosci; 2015 Apr; 69(4):239-40. PubMed ID: 25186635
[No Abstract] [Full Text] [Related]
13. Once-daily memantine: pharmacokinetic and clinical considerations.
Gomolin IH; Smith C; Jeitner TM
J Am Geriatr Soc; 2010 Sep; 58(9):1812-3. PubMed ID: 20863351
[No Abstract] [Full Text] [Related]
14. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
15. Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Choi SH; Park KW; Na DL; Han HJ; Kim EJ; Shim YS; Lee JH;
Curr Med Res Opin; 2011 Jul; 27(7):1375-83. PubMed ID: 21561398
[TBL] [Abstract][Full Text] [Related]
16. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic study of memantine in healthy and renally impaired subjects.
Periclou A; Ventura D; Rao N; Abramowitz W
Clin Pharmacol Ther; 2006 Jan; 79(1):134-43. PubMed ID: 16413248
[TBL] [Abstract][Full Text] [Related]
18. Memantine-induced myoclonus and delirium exacerbated by trimethoprim.
Moellentin D; Picone C; Leadbetter E
Ann Pharmacother; 2008 Mar; 42(3):443-7. PubMed ID: 18303133
[TBL] [Abstract][Full Text] [Related]
19. Minimizing the risk for QT interval prolongation.
Slama TG
J Fam Pract; 2005 Jun; Suppl():S15-7. PubMed ID: 15938990
[TBL] [Abstract][Full Text] [Related]
20. [Alzheimer dementia. Memantine: value for patient and caregivers].
MMW Fortschr Med; 2009 Nov; 151(45):44-5. PubMed ID: 19960725
[No Abstract] [Full Text] [Related]
[Next] [New Search]
